The enantiomeric excess of chiral amines was successfully determined by 1H NMR spectral and/or HPLC analysis of the diastereomeric diamides derived from optically active anti head-to-head coumarin dimer and the amines by lactone-ring-opening reaction without any condensing agent. This procedure also proved to be applicable to chiral alcohols.
通过 1 H NMR 光谱和/或 HPLC 分析衍生自旋光抗头对头香豆素二聚体的非对映体二酰胺和通过内酯开环反应而没有任何缩合剂的胺,成功测定了手性胺的对映体过量。该程序也被证明适用于手性醇。
Thieno-pyrimidine compounds having fungicidal activity
申请人:Brewster Kirkland William
公开号:US20060089370A1
公开(公告)日:2006-04-27
The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.
本发明涉及具有杀真菌活性的噻吩[2,3-d]-嘧啶化合物。
Catalytic asymmetric oxidative carbonylation-induced kinetic resolution of sterically hindered benzylamines to chiral isoindolinones
benzylamines has been achieved for the first time through transition-metal-catalyzed oxidative carbonylation, in which the new KR strategy offered a new approach to afford chiral isoindolinones (er up to 97 : 3) and the origin of chemoselectivity and stereoselectivity was confirmed by density functional theory (DFT) calculations.
ORGANIC PHOSPHORUS COMPOUNDS 106.<sup>1</sup> A <sup>31</sup>P-NMR STUDY OF PHOSPHINOUS-, PHOSPHINIC-, AND THIOPHOSPHINIC AMIDES
作者:Ludwig Maier、Peter J. Diel
DOI:10.1080/10426509608037973
日期:1996.8.1
Abstract The synthesis, physical, chemical and spectroscopic properties of eight different types of phosphinous-, phosphinic- and thiophosphinic amides are reported. It is shown that the 31P-chem. shifts of tertiary amides are at lower magnetic field than that of secondary amides. As an exception, in the bis(tertiary butyl) series this trend is reversed.
[EN] PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDONE CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
申请人:MERCK SHARP & DOHME
公开号:WO2015096651A1
公开(公告)日:2015-07-02
Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.